MedTrace Logo

ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services

NCT06128304 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2436

Last updated 2026-02-10

No results posted yet for this study

Summary

While there has been a significant increase in the uptake of antiretroviral therapy among women living with HIV (WLHIV) in many low- and-middle income countries (LMICs), the coverage of cervical cancer screening and treatment (CCST) among WLHIV remains low. This study aims to leverage the available infrastructure for HIV care and treatment programs in Nigeria to integrate cervical cancer screening and treatment and conduct a cluster randomized, hybrid type III trial design to assess the comparative effectiveness of a Core set of implementation strategies versus a Core+ (enhanced) set of implementation strategies to implement cervical cancer screening, onsite treatment, referral and referral completion, treatment, and retention in care among WLHIV. The overarching goal is to improve the health and life expectancy of WLHIV with co-occurring cervical cancer.

Conditions

Interventions

OTHER

Core Implementation strategies

Core Implementation Strategies 1. Ongoing consultation 2. Educational meetings 3. Strengthen referral system 4. Prepare patients to be active participants

OTHER

Core+ Enhanced Implementation Strategies

Includes all of the Core implementation strategies and adds: 5\. Community engagement using Health Beginning Initiative Model 6\. Smart Cards to facilitate patient engagement

Sponsors & Collaborators

Principal Investigators

  • Gregory Aarons, PhD · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
64 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-13
Primary Completion
2026-12-01
Completion
2027-08-31

Countries

  • United States
  • Nigeria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06128304 on ClinicalTrials.gov